Laboratory of Pharmacogenomics ****************************************************************************************** * ****************************************************************************************** ****************************************************************************************** * Offer ****************************************************************************************** - Research in pharmacogenetics and genomics from the clinical and academic point of view - Isolation of nucleic acids from different types of tissues and cells, especially from cl - Detection of single nucleotide polymorphisms and mutations by allelic discrimination, HR - Quantitative PCR in real-time (qPCR) design and gene expression analysis - Help with interpretation of results of studies on metabolism and transport of anticancer ****************************************************************************************** * Expertise ****************************************************************************************** - Laboratory of Pharmacogenomics is involved in the study and development of prognostic an biomarkers for more refined evaluation of survival of cancer patients and the response of the therapy. Genomic, epigenomic, proteomic, and metabolomic analyses of tissue preparatio patients provided by clinical collaborators from the Czech Republic are performed for this - Predictive biomarkers may help clinicians in the stratification of patients into differe regimens. - Discovery and validation of prognostic biomarkers may also contribute to the invention o targeted therapy. - Our team has experience in this area for more than 20 years. - Research activities are supported by a number of grants including Center of Excellence a Science Foundation. - Lab members regularly publish our results in publicly accessible scientific journals and several highly respected foreign partners. ****************************************************************************************** * Members ****************************************************************************************** - Assoc. Prof. Pavel Souček, Ph.D., M.Sc. – Research Group Leader - Veronika Brynychová, Ph.D., M.Sc. - Pavel Dvořák, Ph.D., M.Sc. - Marie Ehrlichová, M.Sc. - Kateřina Elsnerová, M.Sc. - Viktor Hlaváč, Ph.D., M.Sc. - Simona Šůsová, M.Sc. - Radka Václavíková, Ph.D., M.Sc. ****************************************************************************************** * Selected Publications ****************************************************************************************** - Hubackova M, Vaclavikova R, Ehrlichova M, Mrhalova, Kodet R, Kubackova K, Vrána D, Gut I Association of superoxide dismutases and NAD(P)H oxidoreductases with prognosis of patient carcinomas. Int J Cancer 2012; 130: 338–348 - Hlavata I, Mohelnikova-Duchonova B, Vaclavikova R, Liska V, Pitule P, Novak P, Bruha J, Holubec L, Treska V, Vodicka, P, Soucek P. The role of ABC transporters in progression and of colorectal cancer. Mutagenesis 2012; 27: 187–96 - Vaclavikova R, Ehrlichova M, Hlavata I, Pecha V, Kozevnikovova R, Trnkova M, Adámek J, E Kristensen VN, Gut I and Soucek P. Detection of frequent ABCB1 polymorphisms by high-resol curve analysis and their effect on breast carcinoma prognosis. Clin Chem Lab Med 2012; 50: Brynychová V, Hlaváč V, Ehrlichová M, Václavíková R, Pecha V, Trnková M, Wald M, Mrhalová Pikus T, Kodet R, Kovář J, Souček P. Importance of transcript levels of caspase-2 isoforms breast carcinoma progression. Future Oncol 2013; 9: 427–38 - Hlaváč V, Brynychová V, Václavíková R, Ehrlichová M, Vrána D, Pecha V, Koževnikovová R, J, Kopperová D, Gut I, Souček P. The expression profile of ABC transporter genes in breast Pharmacogenomics 2013; 14: 515–29 - Mohelnikova-Duchonova B, Brynychova V, Oliverius M, Honsova E, Kala Z, Muckova K, Soucek in transcript levels of ABC transporters between pancreatic adenocarcinoma and non-neoplas Pancreas 2013; 42: 707 16 - Ehrlichova M, Mohelnikova-Duchonova B, Hrdy J, Brynychova V, Mrhalova M, Kodet R, Rob L, Soucek P, Vaclavikova R. The association of taxane resistance genes with the clinical cour carcinoma. Genomics. 2013; 102: 96–101 - Mohelnikova-Duchonova B, Brynychova V, Hlavac V, Kocik M, Oliverius M, Hlavsa J, Honsova Kala Z, Melichar B, Soucek P. The association between the expression of solute carrier tra prognosis of pancreatic cancer. Cancer Chemother Pharmacol. 2013; 72: 669–82 - Kunická T, Souček P. Importance of ABCC1 for cancer therapy and prognosis. Drug Metab Re 342 - Kunická T, Václavíková R, Hlaváč V, Vrána D, Pecha V, Rauš K, Trnková M, Kubáčková K, Am L, Vodička P, Souček P. Non-coding polymorphisms in nucleotide binding domain 1 in ABCC1 g with transcript level and survival of patients with breast cancer. Plos One 2014; 9: e1017 - Hlaváč V, Brynychová V, Václavíková R, Ehrlichová M, Vrána D, Pecha V, Trnková M, Kodet Kubáčková K, Gatěk J, Vážan P, Souček P. The role of cytochromes P450 and aldo-keto reduct of breast carcinoma patients. Medicine 2014; 93 (28): e2552014 ****************************************************************************************** * Are you interested in this expertise? ****************************************************************************************** Please contact CPPT UK Web: www.cppt.cuni.cz/ [ URL "https://cppt.cuni.cz/"] Mail: transfer@cuni.cz Phone: +420 224 491 255 ****************************************************************************************** * Experts and their Department ****************************************************************************************** Assoc. Prof. Pavel Souček, Ph.D., M.Sc. Biomedical Center Web: http://www.biomedic-plzen.cz/cz [ URL "http://www.biomedic-plzen.cz/cz"]